Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta BionicsBBNX +0.87%13 EV-to-EBITDA is -9.23 as of Aug. 30, 2026. GuruFocus rates BBNX with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 520 Medical Devices & Instruments companies, Beta Bionics ranks worse than 192307.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beta Bionics's enterprise value is $712.6 Mil.
Beta Bionics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-77.2 Mil. Therefore, Beta Bionics's EV-to-EBITDA for today is -9.23.
The historical rank and industry rank for Beta Bionics's EV-to-EBITDA or its related term are showing as below:
BBNX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.78 Med: -7.57 Max: -1.72
Current: -9.23
During the past 4 years, the highest EV-to-EBITDA of Beta Bionics was -1.72. The lowest was -24.78. And the median was -7.57.
BBNX's EV-to-EBITDA is ranked worse than 100% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 14.66
vs BBNX: -9.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beta Bionics's PE Ratio (TTM) for today is calculated as:
Beta Bionics's share price for today is $19.707.
Beta Bionics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Beta Bionics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Beta Bionics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Bionics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beta Bionics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beta Bionics's EV-to-EBITDA falls into.
Beta Bionics's current Enterprise Value is $712.6 Mil.
Beta Bionics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-77.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Bionics (BBNX) has a EV-to-EBITDA of -9.23 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beta Bionics. According to the industry distribution chart, Beta Bionics ranks #999999 out of 520 companies in the Medical Devices & Instruments industry.
Is Beta Bionics' EV-to-EBITDA too high?
Beta Bionics' current EV-to-EBITDA is -9.23. Based on the distribution chart, Beta Bionics ranks #999999 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beta Bionics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' EV-to-EBITDA compare to SSII and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Beta Bionics ranks #999999 out of 520 companies for EV-to-EBITDA. This places Beta Bionics in the lower half of its industry. The industry median EV-to-EBITDA is 14.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.66, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beta Bionics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Bionics's current EV-to-EBITDA is -9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current EV-to-EBITDA of -9.23. The current EV-to-EBITDA is -9.23. Beta Bionics' overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Beta Bionics (BBNX), the current EV-to-EBITDA is -9.23 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
13GF Score
Get the complete analysis for BBNX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBNX has been successfully added to your 
